Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $3.8 million.

  • Niagen Bioscience's Net Cash Flow fell 15.44% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 466.97%. This contributed to the annual value of $17.3 million for FY2024, which is 151.82% up from last year.
  • As of Q3 2025, Niagen Bioscience's Net Cash Flow stood at $3.8 million, which was down 21.17% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Net Cash Flow ranged from a high of $28.0 million in Q1 2021 and a low of -$7.2 million during Q1 2022.
  • In the last 3 years, Niagen Bioscience's Net Cash Flow had a median value of $3.3 million in 2023 and averaged $4.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 500.57% in 2021, then spiked by 4,472.08% in 2025.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Net Cash Flow stood at -$4.9 million in 2021, then surged by 247.02% to $7.2 million in 2022, then slumped by 92.31% to $552,000 in 2023, then surged by 2,121.38% to $12.3 million in 2024, then declined by 15.44% to $3.8 million in 2025.
  • Its Net Cash Flow stands at $3.8 million for Q3 2025, versus $4.8 million for Q2 2025 and $11.0 million for Q1 2025.